Following the recent approval of U-Systems, Inc.’s new breast-cancer ultrasound by the Food and Drug Administration, the company wasted no time seeking for a major medical-imaging company as partner in their endeavor.
U-Systems had its hands full previously developing a technological device that is specifically designed to effectively detect breast cancer in women with dense tissues. In line with their advocacy to improve breast cancer detection, the California-based company is now on a quest for the right partner to fulfill their goals.
According to Chief Executive Officer Ron Ho, the company is looking for a firm who ventures in women’s health products and services to aid them in marketing the somo-v ABUS breast-cancer ultrasound.
Apparently, the search may soon be over as Ho mentioned that they have received quite a response from several huge medical imaging firms. Moreover, with a product that may promise profits of about $1 Billion, a partnership with U-Systems is more than attractive.
The device was approved by the U.S. regulatory board as an adjunct screening method for women who tested negative on standard mammography. It is set to be priced at $200,000.
Analyst Vijay Kumar of ISI New York remarks that Siemens AG (SIE) of General Electric Co. (GE) may be a likely candidate for the partnerships as the company has maintained an authority in the medical-imaging equipment industry.
Another company with huge potential as U-Systems’ final pick is Hologic, Inc. (HOLX) who has established a name as the pioneer of the 3-D mammography system. However, Kumar claims that the company does not have the ‘balance sheet’, considering the figures involved in their revenues and recent acquisitions.